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Research in context 
Evidence before this study 
We searched PubMed, American Society of Clinical Oncology abstracts, and European Society for Medical 
Oncology abstracts for research articles published in English using the search terms “biliary tract cancer”, 
“cholangiocarcinoma”, “gall bladder cancer”, “capecitabine”, and “adjuvant”. No date restrictions were 
applied. Biliary tract cancer is an uncommon cancer for which surgery is the only potentially curative 
treatment. We found that extant studies have either been statistically underpowered or inadequately 
designed to demonstrate a benefit for adjuvant systemic therapy. 
 
Added value of this study 
 
This randomised, controlled, multicentre, phase 3 study compared capecitabine with observation following 
resection of biliary tract cancer (BILCAP). Although the trial was negative for the prespecified primary 
endpoint (overall survival by intention to treat), the data taken as a whole strongly suggest a benefit of 
adjuvant capecitabine. The study shows that adjuvant capecitabine following surgery with curative intent for 
patient with biliary tract cancer improves overall survival compared with observation in the per-protocol 
population, with a clinically meaningful effect size of 14·7 months. Ongoing exploratory and translational 
analyses of BILCAP will help us to understand both the natural history and the impact of this cancer of unmet 
need. 
 
Implications of all the available evidence 
We believe this study is the first dedicated and sufficiently powered adjuvant study in biliary tract cancer and, 
as such, is uniquely placed to define the standard of care as capecitabine. It is unlikely that another study 
comparing treatment with surveillance will be done, although we await the results of the completed ASCOT 
study, a Japanese Clinical Oncology Group study comparing surveillance with S-1 chemotherapy. 
  
Summary 
Background  
Despite improvements in multidisciplinary management, patients with biliary tract cancer have a poor 
outcome. Only 20% of patients are eligible for surgical resection with curative intent, with 5-year overall 
survival of less than 10% for all patients. To our knowledge, no studies have described a benefit of adjuvant 
therapy. We aimed to determine whether adjuvant capecitabine improved overall survival compared with 
observation following surgery for biliary tract cancer. 
 
Methods  
This randomised, controlled, multicentre, phase 3 study was done across 44 specialist 
hepatopancreatobiliary centres in the UK. Eligible patients were aged 18 years or older and had 
histologically confirmed cholangiocarcinoma or muscle-invasive gallbladder cancer who had undergone a 
macroscopically complete resection (which includes liver resection, pancreatic resection, or, less commonly, 
both) with curative intent, and an Eastern Cooperative Oncology Group performance status of less than 2. 
Patients who had not completely recovered from previous surgery or who had previous chemotherapy or 
radiotherapy for biliary tract cancer were also excluded. Patients were randomly assigned 1:1 to receive oral 
capecitabine (1250 mg/m² twice daily on days 1–14 of a 21-day cycle, for eight cycles) or observation 
commencing within 16 weeks of surgery. Treatment was not masked, and allocation concealment was 
achieved with a computerised minimisation algorithm that stratified patients by surgical centre, site of 
disease, resection status, and performance status. The primary outcome was overall survival. As 
prespecified, analyses were done by intention to treat and per protocol. This study is registered with 
EudraCT, number 2005-003318-13. 
 
Findings  
Between March 15, 2006, and Dec 4, 2014, 447 patients were enrolled; 223 patients with biliary tract cancer 
resected with curative intent were randomly assigned to the capecitabine group and 224 to the observation 
group. The data cutoff for this analysis was March 6, 2017. The median follow-up for all patients was 60 
months (IQR 37–60). In the intention-to-treat analysis, median overall survival was 51·1 months (95% CI 
34·6–59·1) in the capecitabine group compared with 36·4 months (29·7–44·5) in the observation group 
(adjusted hazard ratio [HR] 0·81, 95% CI 0·63–1·04; p=0·097). In a protocol-specified sensitivity analysis, 
adjusting for minimisation factors and nodal status, grade, and gender, the overall survival HR was 0·71 
(95% CI 0·55–0·92; p=0·010). In the prespecified per-protocol analysis (210 patients in the capecitabine 
group and 220 in the observation group), median overall survival was 53 months (95% CI 40 to not reached) 
in the capecitabine group and 36 months (30–44) in the observation group (adjusted HR 0·75, 95% CI 0·58–
0·97; p=0·028). In the intention-to-treat analysis, median recurrence-free survival was 24·4 months (95% CI 
18·6–35·9) in the capecitabine group and 17·5 months (12·0–23·8) in the observation group. In the per-
protocol analysis, median recurrence-free survival was 25·9 months (95% CI 19·8–46·3) in the capecitabine 
group and 17·4 months (12·0–23·7) in the observation group. Adverse events were measured in the 
capecitabine group only, and of the 213 patients who received at least one cycle, 94 (44%) had at least one 
grade 3 toxicity, the most frequent of which were hand-foot syndrome in 43 (20%) patients, diarrhoea in 16 
(8%) patients, and fatigue in 16 (8%) patients. One (<1%) patient had grade 4 cardiac ischaemia or 
infarction. Serious adverse events were observed in 47 (21%) of 223 patients in the capecitabine group and 
22 (10%) of 224 patients in the observation group. No deaths were deemed to be treatment related. 
 
Interpretation  
Although this study did not meet its primary endpoint of improving overall survival in the intention-to- treat 
population, the prespecified sensitivity and per-protocol analyses suggest that capecitabine can improve 
overall survival in patients with resected biliary tract cancer when used as adjuvant chemotherapy following 
surgery and could be considered as standard of care. Furthermore, the safety profile is manageable, 
supporting the use of capecitabine in this setting. 
 
Funding  
Cancer Research UK and Roche. 
 
 
 
  
Introduction 
Biliary tract cancer is an uncommon cancer in high-income countries. There are approximately 1200 and 
9000 new cases per year in the UK and the USA, respectively.1,2 The incidence of biliary tract cancer is 
increasing, perhaps associated with an increasing incidence of gallstone disease. Potentially curative 
resection is feasible in 20% of presenting patients,3 and increasing centralisation of often complex surgery in 
specialist hepatopancreatobiliary centres aims to improve outcomes.4,5 The postoperative median overall 
survival is reported to be 18–30 months, with patients with positive lymph nodes and positive resection 
margins having a worse prognosis.6 
 
The standard of care for patients with unresectable biliary tract cancer has been established as cisplatin and 
gemcitabine, suggesting that biliary tract cancers are chemosensitive malignancies.7,8 However, the value of 
adjuvant chemotherapy has not been investigated in a dedicated randomised trial. A subgroup of the 
ESPAC-3 trial9 comprising 96 patients with biliary tract cancer and the study by Takada and colleagues, 
including 133 patients with non-curative biliary tract cancer resections,10 were not sufficiently statistically 
powered to define a standard of care. More recently, a randomised study11 of gemcitabine compared with 
surveillance in 225 patients with extrahepatic and perihilar cholangiocarcinoma resected with curative intent 
showed no difference in overall survival between the groups (hazard ratio [HR] 1·01, 95% CI 0·70–1·44; 
p=0·97). In addition, a phase 3 trial12 testing adjuvant oxaliplatin plus gemcitabine compared with 
surveillance has recently been reported. Overall survival was not significantly different between the treatment 
groups (HR 1·08, 95% CI 0·70–1·66; p=0·74); however, a large effect size was seen (overall survival of 50·8 
months in the surveillance group vs 75·8 months in the oxaliplatin plus gemcitabine group; HR 1·08, 95% 
CI·70–1·66).12 A meta-analysis13 of mostly non-randomised series has suggested the potential benefit for 
chemo- therapy as adjuvant therapy in patients with biliary tract cancer and node-positive disease, and of 
radiation-based adjuvant therapy in resection margin-positive (R1) subgroups, but given the quality of the 
data included in the analysis, these are still unproven hypotheses. 
 
Capecitabine is an oral fluoropyrimidine prodrug that is effective as adjuvant chemotherapy treatment, either 
alone or in combination, in colorectal,14 oesophageal and gastric,15 and pancreatic9 malignancies. 
Fluoropyrimidines have evidence of activity in biliary tract cancer,10 are well tolerated, and used in everyday 
oncological practice. Although supportive clinical data are scarce, feasibility and compliance with treatment 
were considered crucial in this study and capecitabine was selected as protocol treatment. The BILCAP trial 
aimed to compare capecitabine with observation after resection of biliary tract cancer in specialist 
hepatopancreatobiliary centres in the UK. 
 
Methods 
Study design and participants 
This randomised, controlled, multicentre, phase 3 study was done across 44 specialist 
hepatopancreatobiliary centres in the UK (appendix pp 4–6). Patients aged 18 years or older with 
histologically confirmed cholangiocarcinoma or muscle-invasive gallbladder cancer who had a 
macroscopically complete resection with curative intent were eligible. All patients should have had radical 
surgical treatment, which includes liver resection, pancreatic resection, or, less commonly, both. The Eastern 
Cooperative Oncology Group (ECOG) performance status had to be less than 2, and adequate renal, 
haematological, and liver function was required. Patients with pancreatic or ampullary cancer, mucosal 
gallbladder or unresolved biliary tree obstruction were ineligible. Patients who had not completely recovered 
from previous surgery or who had previous chemotherapy or radiotherapy for biliary tract cancer were also 
excluded. Criteria are described in full in the study protocol (appendix p 7). 
 
Major protocol amendments included extending the start date of chemotherapy from 8 to 12 weeks from the 
date of definitive surgery on Oct 16, 2007, a further extension of study eligibility to 16 weeks after surgery on 
Sept 2, 2008, and the inclusion of extrahepatic cholangiocarcinoma following the completion of the ESPAC-3 
study9 on Aug 26, 2008. These recommendations were made on the basis of the accumulating events during 
patient monitoring rather than in repeated interim analyses. 
 
Randomisation and masking 
Patients were randomly assigned 1:1 to the capecitabine group or the observation group. Treatment was not 
masked, and allocation concealment was achieved using a computerised minimisation algorithm that 
stratified patients by surgical centre, site of disease, resection status, and performance status. Concealment 
remained until the interventions were assigned by a central telephone-based randomisation service hosted 
by the Cancer Research UK Clinical Trials Unit (Birmingham). 
 
Procedures 
Oral capecitabine (1250 mg/m²) was given post- operatively twice a day on days 1 to 14 of a 3-weekly cycle 
for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery. Following 
randomisation, chemotherapy was started as soon as possible after surgery and up to 12 weeks from 
surgery, with a maximum extension to 16 weeks from surgery. The protocol permitted dose modifications 
and cycle interruptions. In cases in which the capecitabine dose was reduced, it was not subsequently 
increased for any reason. In the case of dose interruptions due to toxicity for longer than 2 weeks, the patient 
was considered to be off treatment. There were no criteria for removal of patients from the study. Patients 
had the option to withdraw from trial treatment or follow-up at any stage. Furthermore, criteria for early 
treatment discontinuation, included safety concerns, patient deterioration, and administration of any other 
cancer treatment during the study treatment period. The full list of discontinuation criteria are in the protocol 
(appendix p 7). 
 
All surgery was undertaken in specialist hepatopancreatobiliary centres, mandated in the UK. The surgical 
strategy was to achieve complete microscopic clearance of the disease, including liver or pancreatic 
resection. Patients with less than 1 mm clearance were classified as surgical margin-positive (R1) patients. 
Patients with intrahepatic cholangiocarcinoma underwent hepatectomy, and lymphadenectomy  was not 
mandated for these patients. In the case of hilar cholangiocarcinoma, patients underwent hepatectomy, 
including segment 1, along with radical excision of the extrahepatic biliary tree. Lymphadenectomy was done 
in accordance with local practice. Patients with muscle-invasive gallbladder cancer were treated by 
cholecystectomy when the gallbladder was in situ and hepatectomy, including the gallbladder bed. Excision 
of the extrahepatic biliary tree and the extent of lymphadenectomy was dependent on local practice. Biliary 
tract excision was commonly performed in patients in which the tumour involved the cystic duct. For tumours 
in the lower common bile duct, patients underwent pancreaticoduodenectomy (Whipple’s procedure) with 
excision of the extrahepatic biliary tree and a standard lymphadenectomy. 
 
Postoperative follow-up comprised CT scans every 6 months for the first 24 months and further CT scans at 
annual intervals with clinical review for up to 5 years. CT scans were done every 3 months in year 1,   every 
6 months in year 2, and annually thereafter. Full blood count, biochemistry, and liver function tests were 
done at baseline, at the beginning of each treatment cycle for the capecitabine group, and every 3 months in 
year 1 and every 6 months in year 2 for all patients. Follow-up treatment for patients who had disease 
recurrence was not recorded. Toxicity was categorised according to the National Cancer Institute’s Common 
Toxicity Criteria for Adverse Events, version 3.0. Toxicity was recorded continuously during treatment. 
Serious adverse events were monitored throughout. 
 
Quality of life, recorded over 24 months at the same time as follow-up attendances, was measured using the 
European Organisation for the Research and Treatment of Cancer quality of life questionnaires QLQ-C30 
(designed for all patients with cancer) and QLC-LMC21 (designed for patients with colorectal liver 
metastases). The EuroQoL Quality of Life Scale (EuroQoL-5D-5L) was recorded and used in the preplanned 
health economics analyses only. 
 
This trial was run by the Cancer Research UK Clinical Trials Unit, University of Birmingham (UK), under the 
auspices of the UK National Cancer Research Institute Upper Gastrointestinal Cancer Studies Group and 
sponsored by the University of Southampton (UK). This trial was approved by the West Midlands Multi- 
Centre Research Ethics Committee (05/MRE07/62), and all necessary regulatory approvals were obtained. 
All patients were required to give written informed consent, and the trial was done in accordance with the 
Declaration of Helsinki and the CONSORT and Consolidated Health Economic Evaluation Reporting 
Standards16 guidelines. 
 
Outcomes 
The primary outcome was overall survival, defined as the time from randomisation until the date of death or 
last date of follow-up for surviving patients. Prespecified secondary outcomes included a per-protocol 
analysis of outcomes, recurrence-free survival, toxicity, health economics, and quality of life. Recurrence-free 
survival was defined as the time from randomisation until the date of disease recurrence, death from 
disease, or date of last follow-up. Long-term outcome measures will be reported elsewhere once all surviving 
patients have a minimum follow-up of 60 months. 
 
Statistical analysis 
The initial sample size calculation was based on the assumption that the 24-month overall survival would be 
20% in the observation group,5 and that treatment with capecitabine would improve this outcome by 12%, 
from 20% to 32%. As such, 360  patients and 270 events were needed to detect a HR of 0·71, with a two-
sided significance level of 5% and 80% power. The independent data monitoring committee (IDMC) met 
annually to review safety data and trial progress; no formal interim analyses were done. During the IDMC 
meeting of July, 2013 (at which point 364 patients had been recruited), it became clear that the observed 
number of events was less than originally estimated. Therefore, the IDMC recommended that the final 
analyses be done once 234 events had accrued. This number permitted detection of an increase in overall 
survival from 60% to 71% (HR 0·69), a marginally larger effect than originally planned. The IDMC instructed 
that screening cease in September, 2014, and recruitment in December, 2014. Analyses were done once the 
protocol- specified minimum follow-up period of 2 years was complete. 
 
We did analyses according to the statistical analysis plan (appendix p 83). Primary analyses prespecified by 
protocol were by intention to treat, including all randomised patients. Analyses were also done per protocol, 
which excluded ineligible patients (appendix p 1) and those failing to complete at least one cycle of 
capecitabine (prespecified in the statistical analysis plan). The safety population comprised any patient 
receiving at least one dose of capecitabine. Both groups were monitored for safety, and serious adverse 
event reporting was captured up to a maximum of 9 months from randomisation. With no specific intervention 
delivered, adverse events for toxicity were not monitored in the observation group. 
 
We quantified overall and recurrence-free survival differences as HRs with 95% CIs  estimated  using Cox 
proportional-hazards model with adjustment for minimisation factors. We did not adjust analyses by surgical 
centre because of the large number of participating centres (n=44), leading to flat statistical modelling 
regions. Additionally, we did prespecified sensitivity analyses of overall survival and recurrence-free survival 
in the intention-to-treat population, adjusting the treatment effect for identified prognostic factors (appendix p 
2). We assessed the proportional hazards assumption for overall survival and recurrence-free survival by 
analysing Schoenfeld residuals, and time-varying effects were modelled when the assumption did not hold, 
with specification of time-varying effects guided by visual inspection of –log(–log(S(t))) plots, where S(t) is the 
survival probability at time t. We did preplanned subgroup analyses using adjusted Cox models, with 
heterogeneity tested via interaction terms. Subgroups were age (>60 vs ≤60 years), sex, tumour size (>50 vs 
≤50 mm), nodal status, tumour stage, disease grade, ECOG performance status, resection status, and site of 
disease. 
We assessed each quality-of-life domain by comparison of standardised area under the curve via a Mann-
Whitney test. Economic analysis estimated incremental cost per quality-adjusted life-year (QALY), based on 
overall survival, and quality of life (EuroQoL-5D). Costs included intervention plus UK National Health 
Service use. Economic analyses were adjusted for baseline values, and we assessed uncertainty using cost-
effectiveness acceptability curves. We made no adjustment for multiplicity. The IDMC reviewed the data. No 
formal interim analyses were planned or done. All analyses were done in Stata, version 14. This study is 
registered with EudraCT, number 2005-003318-13. 
 
Role of the funding source 
The funder of the study had an advisory role in study design but no role in the running of the study, data 
collection, data analysis, data interpretation, or writing of the report. Upon completion of patient follow-up, 
JNP, RPF, CS, and JB had full access to all the data and the corresponding authors had final responsibility 
for the decision to submit for publication. 
 
Results 
Between March 15, 2006, and Dec 4, 2014, 447 patients (intention-to-treat population) were enrolled and 
randomly assigned to the capecitabine group (n=223) or the observation group (n=224; figure 1). The per-
protocol population comprised 430 patients (210 in the capecitabine group and 220 in the observation group) 
following the exclusion of 17 patients, comprising seven (2%) patients (three in the capecitabine group and 
four in the observation group) who were found to be ineligible after randomisation (appendix p 1), nine (2%) 
patients who did not receive capecitabine, and one (<1%) patient was ineligible and also received no drug 
(appendix p 1). The required minimum follow-up of 24 months was reached in January, 2017, when the 
median follow-up for all patients was 60 months (IQR 37–60). 
 
Baseline characteristics were well balanced between the two groups (table 1). The median time from surgery 
to randomisation was 10·3 weeks (IQR 8·4–12·1) in the capecitabine group and 10·4 weeks (9·0–12·1) in 
the observation group. 
 
At the time of the final analysis (March 6, 2017), 114 (51%) patients had died in the capecitabine group and 
131 (58%) patients had died in the observation group. Of these deaths, 241 (98%) were related to biliary 
tract cancer (112 in the capecitabine group and 129 in the observation group), two (1%) were due to 
unknown reasons (both in the capecitabine group), and two (1%) resulted from other causes (both in the 
observation group; appendix p 1). In the intention-to-treat analysis, median overall survival was 51·1 months 
(95% CI 34·6–59·1) in the capecitabine group and 36·4 months (29·7–44·5) in the observation group (HR 
0·81, 95% CI 0·63–1·04; p=0·097; figure 2), when adjusted for minimisation factors other than surgical 
centre. Planned sensitivity analyses in the intention-to-treat population explored the effect of identified 
prognostic factors (nodal status, grade of disease, and sex). Adjusting for these and minimisation factors 
resulted in an overall survival HR of 0·71 (95% CI 0·55–0·92; p=0·010). In the per-protocol analysis (figure 
2), median overall survival was 53 months (95% CI 40 to not reached) in the capecitabine group and 36 
months (30–44) in the observation group (adjusted HR 0·75, 95% CI 0·58–0·97; p=0·028).  
 
280 (63%) of 447 patients had disease recurrence (134 [60%] of 223 patients in the capecitabine group and 
146 [65%] of 224 patients in the observation group). In the intention-to-treat analysis, median recurrence-free 
survival was 24·4 months (95% CI 18·6–35·9) in the capecitabine group and 17·5 months (12·0–23·8) in the 
observation group (figure 3). The relative difference in risk between treatment groups differed over time and, 
as such, Cox models with time-varying effects were fitted. The adjusted recurrence-free survival HR was 
0·75 (95% CI 0·58–0·98; p=0·033) in the first 24 months from randomisation, with no evidence of a 
difference in the period from 24 to 60 months (recurrence-free survival HR 1·48, 95% CI 0·80–2·77; p=0·21). 
In the per- protocol analysis, median recurrence-free survival was 25·9 months (95% CI 19·8–46·3) in the 
capecitabine group and 17·4 months (12·0–23·7) in the observation group (figure 3). The adjusted 
recurrence-free survival HR from 0 to 24 months was 0·70 (95% CI 0·54–0·92; p=0·0093), and there was no 
evidence of a difference beyond 24 months (recurrence-free survival HR 1·55, 95% CI 0·82–2·93; p=0·18; 
see appendix pp 1–3 for final overall survival and recurrence-free survival models). 
 
The median capecitabine dose was 1250·0 mg/m² twice daily (IQR 1060·9–1250·0). All but ten (4%) patients 
who started capecitabine received at least one cycle of capecitabine, and 122 (55%) patients completed 
eight cycles of capecitabine. Of the 213 patients who started treatment, 99 (46%) had at least one dose 
reduction. Of the 69 (32%) who discontinued treatment because of toxicity, the most common complaints 
were hand-foot syndrome in ten patients (14%), diarrhoea in nine patients (13%), and other (patients could 
cite more than one toxicity type) in 21 (31%) patients. 
 Adverse events were only recorded in the capecitabine group, and serious adverse events were recorded in 
both groups. Treatment toxicity was assessed in the safety population (213 patients in the capecitabine 
group), and 212 patients reported 4694 toxicities. The grade was unknown in 21 (<1%) events. Of the 213 
patients, 94 (44%) had at least one grade 3 toxicity, and one patient (<1%) had grade 4 cardiac ischaemia or 
infarction (table 2). The most frequent grade 3 events were hand-foot syndrome in 43 (20%) of 213 patients, 
diarrhoea in 16 (8%) patients, or fatigue in 16 (8%) patients. Serious adverse events were observed in 47 
(21%) of 223 patients (64 events) in the capecitabine group and 22 (10%) of 224 patients (29 events) in the 
observation group. Of the 64 serious adverse events in the capecitabine group, 33 (52%) were related to 
treatment and, of those, five (8%) were cardiac events related to capecitabine (table 3). None of the serious 
adverse events in the capecitabine group resulted in death, and three (10%) of those reported in the 
observation group resulted in death (appendix p 4). 
 
Prespecified subgroup analyses of clinical factors are presented in the forest plot (figure 4). In the intention-
to- treat population, benefit of capecitabine was indicated in men (HR 0·70, 95% CI 0·50–0·99) and those 
with poorly differentiated disease (0·60, 0·39–0·93). There was no statistical evidence of heterogeneity. 
1915 quality-of-life questionnaires were returned by 433 (97%) of 447 patients (216 [97%] of 223 in the 
capecitabine group and 217 [97%] of 224 in the observation group). Area under the curve was standardised 
by time, and hence the standardised area under the curve is interpreted as the average monthly quality of 
life. The full set of results is provided in table 4. Statistically significant differences were observed in the 
social functioning scale of the QLQ-C30, with a median standardised area under the curve of 76·2 (IQR 
56·9–91·7) in the capecitabine group and 83·3 (64·6–95·8) in the observation group (p=0·0060). Analyses of 
QLQ-LMC-21 identified increased taste symptoms in the capecitabine group (p=0·042), with a median 
standardised area under the curve of  0·0 (IQR 0·0–11·1) in the capecitabine group and 0·0 (0·0–6·3) in the 
observation group, and peripheral neuropathy (p=0·0016) with a median standardised area under the curve 
of 0·0 (0·0–13·5) in the capecitabine group and 0·0 (0·0–4·2) in the observation group, although peripheral 
neuropathy should be interpreted as hand-foot syndrome. These statistical differences in quality of life are 
unlikely to have translated into clinical significance. No other statistically significant differences were 
observed (table 4). 
The mean QALY gain at 2 years was 0·035 (95% CI–0·034 to 0·104), leading to an incremental cost per 
QALY of just under £13 300 (US$17 200). Linear extrapolation to 5 years reduced the incremental cost per 
QALY to £2725 ($3538). The cost effectiveness accept- ability curve indicated a probability of more than 
90% of capecitabine being cost-effective at willingness to pay more than £18 000 ($23 377; appendix p 4). 
 
Discussion 
The BILCAP study, which compared capecitabine with observation as an adjuvant in biliary tract cancer 
resected with curative intent, provides evidence that capecitabine can improve overall survival. Although the 
overall survival primary endpoint analysed in the intention-to- treat population did not reach statistical 
significance, the sensitivity analyses of this population, the per-protocol overall survival and recurrence-free 
survival analyses showed benefit, and the overall survival effect size of 14·7 months is clinically meaningful. 
The intention-to- treat (statistically negative) and per-protocol (statistically positive) populations differed by 17 
patients who were either found to be ineligible (appendix p 1) or were randomly assigned to but did not 
receive capecitabine. Of the patients who did not receive capecitabine, the most common reason cited was 
that the patient no longer wished to participate in the trial (appendix p 1). 
 
The intention-to-treat and per-protocol analyses revealed no evidence of a difference in recurrence-free 
survival in the period between 24 and 60 months, suggesting that deferred recurrence occurred in the 
capecitabine group. This finding will be explored in the long-term survival analyses to be reported once 5 
years of follow-up has been met. 
 
The limitations of this study include the long recruitment period of 10 years, during which time approaches to 
the clinical trial process have become more defined. An unintended consequence is that the protocol, which 
was acceptable when written in 2005, can be criticised; for example, there was no fully defined statistical 
analysis plan when the study started, but it is mandatory in a 2019 study. Additionally, the heterogeneity of 
biliary tract cancers, both surgically and, more recently, biologically, makes an overall interpretation of our 
findings more complex. Furthermore, the surgical centre was not included in the modelling analyses adjusted 
for minimisation factors. 
 
Adverse events were modest, and the incidence of some potentially serious toxic effects such as 
fluoropyrimidine-related cardiac vasospasm was significantly less than seen in similar studies, perhaps 
because any serious cardiac comorbidity had been unmasked in preparation for and during 
hepatopancreatobiliary surgery. Although some significant changes in quality of life were observed, the 
differences were modest and support a tolerable and deliverable regimen that is cost-effective. Compliance 
to capecitabine in BILCAP was lower than for colorectal cancer14 but equivalent to that for patients who had 
undergone hepatopancreatobiliary surgery.9 Further analysis of dose intensity to determine any effect on 
outcome will be reported elsewhere. 
 
We have reported median overall survival of more than 50 months following potentially curative surgery for 
biliary tract cancer, which suggests an improvement on historical controls that is likely to be a reflection of 
improved surgical selection and management, as well as the patient selection criteria (fitness) required for 
the study. Centralisation in the care of complex medicine has resulted in improved outcomes,5 specifically for 
cancer surgery, and has been the principle behind the establishment of specialist hepatopancreatobiliary 
centres in the UK. This improvement became apparent during recruitment and required a protocol 
amendment changing the observed 2-year survival in the observation group from 20% to 60%. Additionally, 
during the recruitment period, the standard of care in advanced disease was established as cisplatin and 
gemcitabine, which might have affected the unanticipated improvement in overall survival.7,8 
 
Biliary tract cancer is an uncommon cancer and, as reflected by the BILCAP study duration as well as the 
experience of other investigators, adjuvant studies are challenging. Although BILCAP was not a statistically 
positive study by the primary intention-to-treat analysis, the position of equipoise among oncologists might 
be sufficiently affected by the weight of the overall positive body of BILCAP data as to render a future study 
with an observation group unfeasible. We note that the control group in the current European adjuvant 
study17 has been changed to capecitabine from observation, perhaps for this reason. We believe that the 
body of BILCAP data as a whole is sufficient to propose a benefit for adjuvant capecitabine as a standard of 
care in the adjuvant management of biliary tract cancer resected with curative intent. 
 
Biliary tract cancer is emerging as a biologically heterogeneous group of cancers,18 which perhaps explains 
the failure of targeted therapies in unselected patient populations to demonstrate benefit in advanced 
disease,19–21 although there is promise in selected populations.22,23 The translational research outcomes for 
BILCAP are therefore crucial for the future testing of more effective therapies. 
 
In summary, although the BILCAP study did not meet its primary endpoint of improving overall survival in the 
intention-to-treat population, the sensitivity and secondary analyses suggest that capecitabine can improve 
overall survival in resected biliary tract cancer when used as adjuvant chemotherapy following surgery and 
could be considered as standard of care. Furthermore, the safety profile is manageable and the quality of life 
data favourable, supporting the use of capecitabine in this setting. 
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 Figure 1: Trial profile 
 
 
 
  
  
Figure 2: Overall survival by intention-to-treat (A) and per-protocol (B) analyses 
HR=hazard ratio. 
  
 Figure 3: Recurrence-free survival by intention-to-treat (A) and per-protocol (B) analyses 
HR=hazard ratio. 
 
  
  
Figure 4: Subgroup analyses of overall survival in the intention-to-treat population 
Heterogeneity assessed through fitting of interactions terms in Cox survival models. ECOG=Eastern 
Cooperative Oncology Group. HR=hazard ratio. R0=negative resection margin. R1=positive resection 
margin. 
 
  
 Capecitabine group 
(n=223) 
Observation group 
(n=224) 
Sex   
 Female 112 (50%) 111 (50%) 
 Male 111 (50%) 113 (50%) 
Age, years 62 (55–68) 64 (55–69) 
Primary tumour site   
 Intrahepatic cholangiocarcinoma 43 (19%) 41 (18%) 
 Hilar cholangiocarcinoma 65 (29%) 63 (28%) 
 Muscle-invasive gallbladder carcinoma 39 (17%) 40 (18%) 
 Mucosal gallbladder carcinoma 0 0 
 Lower common bile duct cholangiocarcinoma 76 (34%) 80 (36%) 
Resection status   
 R0 139 (62%) 140 (63%) 
 R1 84 (38%) 84 (38%) 
ECOG performance status   
 0 100 (45%) 101 (45%) 
 1 116 (52%) 116 (52%) 
 2 7 (3%) 7 (3%) 
Tumour stage   
 I 57 (26%) 61 (27%) 
 II 137 (61%) 144 (64%) 
 III 28 (13%) 18 (8%) 
 IV 1 (<1%) 0 
 Missing data 0 1 (<1%) 
Lymph node status   
 N0 115 (52%) 121 (54%) 
 N1 108 (48%) 102 (46%) 
 Missing data 0 1 (<1%) 
Disease grade   
 Well differentiated 34 (15%) 36 (16%) 
 Moderately differentiated 110 (49%) 120 (54%) 
 Poorly differentiated 64 (29%) 56 (25%) 
 Not determined 12 (5%) 9 (4%) 
 Not known 3 (1%) 2 (1%) 
 Missing data 0 1 (<1%) 
Haemoglobin (g/dL) 12 (12–13) 13 (12–14) 
White blood cell count, × 10 9 cells per L  7 (6–8) 7 (6–8) 
Absolute neutrophil count, × 10 9 cells per L  4 (3–5) 4 (3–5) 
Platelet count, × 10 9 per L  279 (231–346) 280 (243–343) 
Glomerular filtration rate, mL/min 92 (77–113) 94 (77–111) 
Aspartate aminotransferase, U/L 27 (22–35) 27 (20–38) 
Alanine aminotransferase, U/L 27 (20–41) 26 (18–40) 
Bilirubin, μmol/L 8 (6–10) 8 (5–11) 
Creatinine, μmol/L 67 (58–76) 67 (58–77) 
Tumour size, mm 25 (19–45) 25 (20–44) 
Resection type   
 Liver 129 (58%) 124 (55%) 
 Pancreas 92 (41%) 97 (43%) 
 Other 2 (1%) 2 (1%) 
 Missing data 0 1 (<1%) 
 
Data are n (%) or median (IQR). N0=negative. N1=positive. R0=negative resection margin. R1=positive 
resection margin. ECOG=Eastern Cooperative Oncology Group. 
 
Table 1: Baseline characteristics 
 
 Grade 1 and 2 Grade 3 
Hand-foot syndrome 127 (60%) 43 (20%) 
Fatigue 159 (75%) 16 (8%) 
Diarrhoea 121 (57%) 16 (8%) 
Gastrointestinal or abdominal 
pain not otherwise specified 61 (29%) 10 (5%) 
Neutrophils or granulocytes 45 (21%) 4 (2%) 
Bilirubin 42 (20%) 3 (1%) 
Nausea 106 (50%) 2 (1%) 
Oral mucositis or stomatitis 94 (44%) 2 (1%) 
Skin rash or desquamation 
(dermatology) 31 (15%) 2 (1%) 
Insomnia (constitutional 
symptoms) .. 2 (1%) 
Gastrointestinal ascites .. 2 (1%) 
Biliary sepsis .. 2 (1%) 
Vomiting 49 (23%) 1 (<1%) 
Fever 30 (14%) 1 (<1%) 
Low platelet count 25 (12%) 1 (<1%) 
Dry skin (dermatology/skin) .. 1 (<1%) 
Lip swelling (dermatology/skin) .. 1 (<1%) 
Gastrointestinal dehydration .. 1 (<1%) 
Gastrointestinal obstruction .. 1 (<1%) 
Infection .. 1 (<1%) 
Limb oedema (lymphatics) .. 1 (<1%) 
Alanine aminotransferase 
(metabolic/laboratory) .. 1 (<1%) 
Aspartate aminotransferase 
(metabolic/laboratory) .. 1 (<1%) 
Alkaline phosphatase 
(metabolic/laboratory) .. 1 (<1%) 
Low serum potassium 
(metabolic/laboratory) .. 1 (<1%) 
γ-glutamyltransferase 
(metabolic/laboratory) .. 1 (<1%) 
Ischaemic cardiac pain .. 1 (<1%) 
General pain .. 1 (<1%) 
Musculoskeletal back pain .. 1 (<1%) 
Musculoskeletal joint pain .. 1 (<1%) 
Vascular thrombosis or embolism .. 1 (<1%) 
 
Data are n (%). All grade 3 events are reported. Only those grades 1 and 2 events experienced by 10% or 
more of patients are reported. One (<1%) patient had grade 4 cardiac ischaemia or infarction. No grade 5 
adverse events were reported. 
 
Table 2: Adverse events in the capecitabine group (n=213) 
 
 
 
 
 
 Capecitabine group 
(n=64)  
Observation group 
(n=29)  
Category    
Unrelated serious adverse event 31 (48%) 29 (100%) 
Serious adverse reaction 33 (52%) 0 
Outcome    
Resolved, no sequelae 55 (86%) 12 (41%) 
Resolved, with sequelae 6 (9%) 10 (34%) 
Unresolved 3 (5%) 4 (14%) 
Death 0 3 (10%) 
Relatedness to treatment    
Unrelated 23 (36%) NA 
Unlikely to be related 14 (22%) NA 
Possibly related 5 (8%) NA 
Probably related 7 (11%) NA 
Definitely related 15 (23%) NA 
Expectedness    
Expected 51 (80%) NA 
Unexpected 5 (8%) NA 
Missing data 8 (13%) NA 
 
Data are n (%). Numbers are the frequency of events; patients might have more than one serious adverse 
event. NA=not applicable. 
 
Table 3: Serious adverse events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Capecitabine group (n=223) 
Observation group 
(n=224) p value 
QLQ-LMC21     
Eating 1·0 (0·0–12·5) 0·0 (0·0–9·4) 0·18 
Pain 11·1 (0·0–26·0) 4·9 (0·0–22·2) 0·061 
Fatigue 16·7 (0·0–36·1) 10·1 (0·0–31·3) 0·066 
Social functioning 3·5 (0·0–15·6) 0·0 (0·0–13·9) 0·11 
Anxiety 14·3 (0·0–36·7) 12·5 (0·0–30·2) 0·25 
Weight loss 0·0 (0·0–9·4) 0·0 (0·0–6·3) 0·11 
Taste 0·0 (0·0–11·1) 0·0 (0·0–6·3) 0·042 
Dry mouth 0·0 (0·0–16·7) 0·0 (0·0–13·9) 0·26 
Sore mouth or tongue 0·0 (0·0–4·2) 0·0 (0·0–4·2) 0·59 
Peripheral neuropathy 0·0 (0·0–13·5) 0·0 (0·0–4·2) 0·0016 
Jaundice 0·0 (0·0–0·0) 0·0 (0·0–0·0) 0·92 
QLQ-C30 functioning scales     
Physical 82·5 (64·0–92·7) 85·0 (70·0–93·3) 0·16 
Role 72·9 (50·5–91·7) 81·3 (52·8–91·7) 0·18 
Emotional 79·9 (58·9–92·2) 83·3 (64·8–93·2) 0·36 
Cognitive 87·5 (66·1–96·4) 87·5 (76·0–100·0) 0·1 
Social 76·2 (56·9–91·7) 83·3 (64·6–95·8) 0·0060 
Global health status or quality of life 67·9 (52·1–80·6) 70·8 (56·3–83·3) 0·18 
QLQ-C30 symptoms scales     
Fatigue 27·8 (15·0–43·3) 27·1 (11·1–38·9) 0·27 
Nausea and vomiting 2·8 (0·0–11·3) 1·4 (0·0–8·3) 0·27 
Pain 17·7 (5·2–38·2) 16·7 (6·3–33·3) 0·8 
Dyspnoea 6·3 (0·0–25·0) 8·3 (0·0–25·0) 0·43 
Insomnia 21·9 (4·9–44·1) 20·8 (5·6–41·7) 0·8 
Appetite loss 6·3 (0·0–18·8) 8·3 (0·0–20·8) 0·88 
Constipation 4·2 (0·0–22·9) 2·1 (0·0–16·7) 0·62 
Diarrhoea 8·3 (0·0–16·7) 4·2 (0·0–16·7) 0·36 
Financial difficulties 2·1 (0·0–22·2) 0·0 (0·0–18·8) 0·35 
 
Data are median (IQR) standardised area under the curve unless otherwise specified. p values were 
calculated from the Mann-Whitney test comparing the standardised area under the curve between treatment 
groups. All scales of the European Organisation for Research and Treatment of Cancer quality-of-life 
questionnaires QLQ-LMC21 and QLQ-C30 are shown. 
 
Table 4: Patient-reported outcomes 
 
 
 
 
 
 
 
